INmune Bio, Inc. (INMB) Q2 2025 Earnings Call Transcript

INmune Bio reported a Q2 2025 net loss of $24.5 million, significantly higher than Q2 2024, largely due to a $16.5 million impairment charge on its XPro Alzheimer's asset. This write-off stems from the company's decision to halt internal Phase III development of XPro for Alzheimer's, despite Phase II data showing efficacy in a targeted neuroinflammatory subgroup, as it now seeks strategic partnerships for the costly program. New CEO David Moss affirmed this strategic shift, with cash sufficient into Q3 2026. Concurrently, INmune Bio is advancing CORDStrom towards mid-2026 BLA/MAA filings for Recessive Dystrophic Epidermolysis Bullosa, while closing its INKmune prostate cancer trial to re-evaluate its use in earlier disease stages.

Analysis

INmune Bio is undergoing a significant strategic and leadership transition following its Q2 2025 results. The appointment of David Moss as the new CEO coincides with major pivots for two of its three core pipeline assets. The Phase II MINDFuL trial for its Alzheimer's drug, XPro, failed to meet its primary endpoint in the overall population, attributed by management to a lack of decline in the placebo group. However, the company highlighted a positive signal in a key subgroup of patients with high inflammation, noting effect sizes of 0.27 on the EMACC and 0.23 on the NPI. Despite this, the high cost of a Phase III trial has prompted the company to halt further internal development and seek a strategic partner. This decision is underscored by a substantial $16.5 million impairment charge, writing off the intangible asset value of XPro and contributing to a widened quarterly net loss of $24.5 million. Concurrently, the INKmune oncology program is also being reset; its Phase I/II trial in late-stage prostate cancer is being closed to recruitment after failing to show a significant impact on disease burden, shifting focus to earlier-stage disease. The company's most promising near-term asset now appears to be CORDStrom for RDEB, with a clear timeline targeting BLA/MAA filings by mid-2026 and the potential for a valuable Priority Review Voucher. With a cash balance of $33.4 million providing a runway into Q3 2026, the company's financial stability hinges on disciplined execution and securing non-dilutive funding or partnerships.

Key Decisions for Investors

• The investment thesis for XPro is now contingent on INmune Bio securing a strategic partnership, as the company has halted internal development and taken a significant write-down; monitor for news following the end-of-Phase II FDA meeting expected in Q4 2025.
• Investors should view CORDStrom as the primary near-term value driver, focusing on the company's ability to meet its mid-2026 BLA/MAA submission timeline and the potential monetization of a Priority Review Voucher.
• Given the strategic pivots in the XPro and INKmune programs, and a cash runway extending only to Q3 2026, be mindful of execution risk under the new CEO and the high probability of future financing needs, which could lead to dilution.
• The decision to discontinue development of XPro for treatment-resistant depression and pivot the INKmune program to earlier-stage cancer indicates a strategic refocus on capital efficiency and probability of success, which should be monitored for tangible progress.